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Validated Risk Score for Predicting 6-Month Mortality in Infective
Endocarditis
Lawrence P. Park, PhD; Vivian H. Chu, MD, MHS; Gail Peterson, MD; Athanasios Skoutelis, MD, PhD; Tatjana Lejko-Zupa, MD, PhD;
Emilio Bouza, MD, PhD; Pierre Tattevin, MD; Gilbert Habib, MD; Ren Tan, MBBS; Javier Gonzalez, MD; Javier Altclas, MD;
Jameela Edathodu, MBBS; Claudio Querido Fortes, MD; Rinaldo Focaccia Siciliano, MD, PhD; Orathai Pachirat, MD; Souha Kanj, MD;
Andrew Wang, MD; for the International Collaboration on Endocarditis (ICE) Investigators*
Background-—Host factors and complications have been associated with higher mortality in infective endocarditis (IE). We sought
to develop and validate a model of clinical characteristics to predict 6-month mortality in IE.
Methods and Results-—Using a large multinational prospective registry of deﬁnite IE (International Collaboration on Endocarditis
[ICE]–Prospective Cohort Study [PCS], 2000–2006, n=4049), a model to predict 6-month survival was developed by Cox
proportional hazards modeling with inverse probability weighting for surgery treatment and was internally validated by the
bootstrapping method. This model was externally validated in an independent prospective registry (ICE-PLUS, 2008–2012,
n=1197). The 6-month mortality was 971 of 4049 (24.0%) in the ICE-PCS cohort and 342 of 1197 (28.6%) in the ICE-PLUS cohort.
Surgery during the index hospitalization was performed in 48.1% and 54.0% of the cohorts, respectively. In the derivation model,
variables related to host factors (age, dialysis), IE characteristics (prosthetic or nosocomial IE, causative organism, left-sided valve
vegetation), and IE complications (severe heart failure, stroke, paravalvular complication, and persistent bacteremia) were
independently associated with 6-month mortality, and surgery was associated with a lower risk of mortality (Harrell’s C statistic
0.715). In the validation model, these variables had similar hazard ratios (Harrell’s C statistic 0.682), with a similar, independent
beneﬁt of surgery (hazard ratio 0.74, 95% CI 0.62–0.89). A simpliﬁed risk model was developed by weight adjustment of these
variables.
Conclusions-—Six-month mortality after IE is 25% and is predicted by host factors, IE characteristics, and IE complications.
Surgery during the index hospitalization is associated with lower mortality but is performed less frequently in the highest risk
patients. A simpliﬁed risk model may be used to identify speciﬁc risk subgroups in IE. ( J Am Heart Assoc. 2016;5:e003016 doi:
10.1161/JAHA.115.003016)
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I nfective endocarditis (IE) remains a serious disease dueto its high morbidity and mortality.1 Despite improve-
ments in diagnostic testing, antimicrobial treatment, and
surgical intervention, changes in the epidemiology of IE,
including the rise of health care–associated infection and
Staphylococcus aureus as a virulent causative organism,2,3
increase the risk of complications and death in the acute
phase of IE. Furthermore, survival after hospital discharge
may be reduced by late complications and comorbid
conditions.4,5
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In patients with active IE, complications such as heart
failure, abscess formation, and embolic events portend poor
prognosis and are regarded as indications for surgical
intervention to improve the chance of survival.6,7 These
complications have been associated with increased in-
hospital mortality, yet their impact on longer term outcome
is not well deﬁned. Although previous studies have developed
risk models for IE survival, these studies have been limited by
retrospective data collection, limited sample size, regional
selection bias, and variable adjustment for surgical interven-
tion.8,9
We hypothesized that speciﬁc clinical characteristics of an
IE episode, including surgical intervention, would be asso-
ciated with 6-month mortality in IE. Using 2 separate
prospective multinational registries of deﬁnite IE, the objec-
tive of this study was to develop and validate a risk model for
6-month mortality in IE.
Methods
Study Populations and Clinical Data
The study populations for this analysis were obtained from the
International Collaboration on Endocarditis (ICE)–Prospective
Cohort Study (PCS) and ICE-PLUS cohorts. These 2 prospec-
tive multinational registries collected consecutive cases of
deﬁnite IE by modiﬁed Duke criteria,10 with prespeciﬁed
deﬁnitions of variables, as described previously.3,11 For the
Table 1. Demographic and Clinical Characteristics of IE Patients in the International Collaboration on Endocarditis–Prospective
Cohort Study Cohort
Variable
Overall
n=4049
Alive
n=3077
Died (6 Months)
n=971 OR (95% CI) P Value
Age, y (range) 59 (45–72) 57 (42–69) 68 (53–76) – <0.001
Male 2752 (68.1) 2134 (69.4) 617 (63.7) 0.77 (0.66–0.90) <0.001
First clinical manifestation ≥1 month 890 (22.9) 764 (25.8) 126 (13.6) 0.45 (0.37–0.56) <0.001
Prosthetic valve IE 967 (23.9) 676 (22.0) 291 (30.0) 1.52 (1.29–1.79) <0.001
Transfer from other hospital 1780 (44.4) 1379 (45.3) 401 (41.7) 0.86 (0.74–1.00) 0.049
Hospital acquired 576 (14.3) 340 (11.1) 236 (24.5) 2.66 (2.15–3.14) <0.001
Previous IE 342 (8.5) 267 (8.7) 75 (7.8) 0.88 (0.67–1.16) 0.39
Diabetes mellitus 689 (17.3) 437 (14.4) 252 (26.5) 2.14 (1.78–2.56) <0.001
Moderate or severe renal disease 357 (19.2) 188 (13.8) 169 (34.2) 3.24 (2.53–4.16) <0.001
Hemodialysis dependent 297 (7.5) 157 (5.2) 140 (14.6) 3.14 (2.45–4.02) <0.001
HIV 85 (2.1) 63 (2.1) 22 (2.3) 1.12 (0.65–1.85) 0.70
Injection drug use 414 (10.4) 354 (11.6) 60 (6.3) 0.52 (0.38–0.69) <0.001
New moderate or severe aortic or mitral regurgitation 2387 (59.4) 1804 (59.1) 583 (60.6) 1.07 (0.92–1.24) 0.41
Aortic valve vegetation 1644 (41.1) 1250 (41.1) 394 (41.3) 1.01 (0.87–1.17) 0.94
Mitral valve vegetation 1763 (44.2) 1277 (42.0) 486 (51.1) 1.44 (1.24–1.67) <0.001
Staphylococcus aureus 1218 (30.1) 808 (26.3) 409 (42.1) 2.04 (1.75–2.38) <0.001
Coagulase-negative Staphylococcus 379 (9.4) 272 (8.8) 107 (11) 1.28 (1 .00–1.62) 0.043
Viridans group streptococcus 699 (17.3) 617 (20.1) 82 (8.4) 0.37 (0.28–0.47) <0.001
New or worsening heart failure 1316 (33.2) 833 (27.5) 483 (51.5) 2.88 (2.40–3.26) <0.001
NYHA class 3 or 4 878 (23.3) 516 (17.8) 362 (41.9) 3.34 (2.82–3.95) <0.001
Paravalvular complication 974 (24.4) 688 (22.6) 286 (30.0) 1.47 (1.24–1.73) <0.001
Intracardiac abscess 634 (16.0) 411 (13.6) 223 (23.8) 1.99 (1.65–2.40) <0.001
Persistent bacteremia 370 (9.3) 208 (6.9) 162 (17.2) 2.81 (2.24–3.52) <0.001
Stroke 776 (19.5) 467 (15.44) 309 (32.7) 2.67 (2.25–3.17) <0.001
Embolization 1001 (25.3) 741 (24.55) 260 (27.8) 1.18 (1.00–1.40) 0.048
Surgery this IE episode 1949 (48.4) 1574 (51.4) 375 (38.9) 0.66 (0.52–0.70) <0.001
HIV indicates human immunodeﬁciency virus; IE, infective endocarditis; NYHA, New York Heart Association; OR, odds ratio.
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derivation cohort, the ICE-PCS registry included 5676 patients
from 64 centers in 28 countries who were hospitalized
between June 2000 and December 2006 for deﬁnite IE and
who had vital status follow-up information available at 1 year
after discharge. For the validation cohort, the ICE-PLUS
registry included 2124 IE patients from 34 centers in 18
countries who were hospitalized between September 1, 2008,
and December 31, 2012, and who had 6-month vital status
follow-up data (all ICE sites listed in the Appendix). Patients
with device-related IE were excluded from the analyses. The
study was approved by the institutional review board or ethics
committee at each participating site, according to local
standards.
Statistical Analysis
Descriptive statistics
Baseline characteristics and clinical events are presented as
medians with 25th and 75th percentiles for continuous
variables and frequencies with proportions for categorical
Table 2. Demographic and Clinical Characteristics of IE Patients in the International Collaboration on Endocarditis–PLUS Cohort
Variable
Overall
n=1197
Alive
n=849
Died (6 Months)
n=342 OR (95% CI) P Value
Age, y 62 (46–73) 59 (44–71) 68 (54–76) – <0.001
Male 815 (68.3) 602 (71.1) 209 (61.3) 0.64 (0.49–0.85) 0.001
First clinical manifestation ≥1 month 396 (33.6) 300 (35.8) 95 (28.4) 0.71 (0.53–0.94) 0.017
Prosthetic valve IE 348 (29.1) 226 (26.6) 120 (35.1) 1.49 (1.13–1.97) 0.005
Transfer from other hospital 591 (49.7) 427 (50.5) 162 (48.1) 0.91 (0.70–1.18) 0.479
Hospital acquired 193 (16.3) 101 (12.1) 91 (26.6) 2.65 (1.90–3.68) <0.001
Previous endocarditis 111 (9.4) 83 (9.9) 28 (8.3) 0.83 (0.51–1.32) 0.442
Diabetes mellitus 236 (20.0) 136 (16.2) 98 (29.1) 2.12 (1.55–2.88) <0.001
Moderate or severe renal disease 147 (12.5) 70 (8.3) 76 (22.9) 3.27 (2.25–4.73) <0.001
Hemodialysis dependent 62 (5.2) 31 (3.7) 31 (9.1) 2.63 (1.52–4.55) <0.001
HIV 23 (2.0) 18 (2.2) 4 (1.2) 0.56 (0.14–1.72) 0.348
Injection drug use 74 (6.3) 57 (6.8) 15 (4.5) 0.65 (0.34–1.18) 0.177
New moderate or severe aortic or mitral regurgitation 675 (58.6) 485 (59.1) 187 (57.2) 0.93 (0.71–1.21) 0.596
Aortic valve vegetation 504 (42.6) 344 (40.9) 157 (46.7) 1.27 (0.97–1.65) 0.078
Mitral valve vegetation 555 (46.8) 383 (45.4) 172 (51.0) 1.27 (0.97–1.65) 0.140
Staphylococcus aureus 279 (23.3) 167 (19.7) 110 (32.2) 1.94 (1.44–2.59) <0.001
Coagulase-negative Staphylococcus 102 (8.5) 65 (7.7) 36 (10.5) 1.42 (0.90–2.21) 0.109
Viridans group streptococcus 189 (15.8) 152 (17.9) 36 (10.5) 0.54 (0.36–0.80) 0.002
New or worsening heart failure 456 (38.9) 289 (34.4) 165 (50.3) 1.93 (1.47–2.52) <0.001
NYHA Class 3 or 4 72 (6.2) 38 (4.6) 34 (10.3) 2.39 (1.43–3.98) <0.001
Paravalvular complication 410 (34.7) 282 (33.5) 126 (37.4) 1.18 (0.90–1.55) 0.223
Intracardiac abscess 380 (32.1) 252 (30.1) 126 (37.2) 1.38 (1.04–1.81) 0.019
Persistent bacteremia 141 (12.7) 78 (9.7) 63 (21.0) 2.49 (1.70–3.63) <0.001
Stroke 260 (22.2) 152 (18.1) 106 (32.5) 2.18 (1.61–2.94) <0.001
Embolization 400 (33.8) 295 (34.8) 102 (30.7) 0.83 (0.62–1.10) 0.193
Surgery for this IE episode 647 (54.6) 499 (59.5) 146 (42.9) 0.51 (0.39–0.67) <0.001
HIV indicates human immunodeﬁciency virus; IE, infective endocarditis; NYHA, New York Heart Association; OR, odds ratio.
Table 3. Types of Cardiac Surgeries for Infective Endocarditis
Type of Valve Surgery ICE-PCS (n=1807) ICE-PLUS (n=621)
Aortic valve replacement 778 (43%) 246 (40%)
Mitral valve replacement 403 (22%) 136 (22%)
Mitral valve repair 89 (5%) 37 (6%)
Multiple valve replacement/repair 413 (23%) 171 (28%)
ICE indicates International Collaboration on Endocarditis; PCS, Prospective Cohort Study.
DOI: 10.1161/JAHA.115.003016 Journal of the American Heart Association 3
IE Mortality Risk Score Park et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
variables. Statistical comparisons between groups were made
with the Wilcoxon rank sum test for continuous variables and
the Fisher exact test for categorical variables.
Propensity score models
A multivariable logistic regression model was ﬁt in the ICE-
PCS and ICE-PLUS data sets independently to calculate a
propensity score (probability) for surgical treatment. The
response variable was receipt of surgery during the index
hospitalization. The model included variables that were
selected a priori by an experienced cardiologist (A.W.) and
from practice guidelines6,7 and previous studies1,12,13
because those would be evaluated in the decision to treat
IE with surgery. These variables were age >70 years, history
of hemodialysis, history of intravenous drug use, time of
≥1 month since ﬁrst IE manifestation, paravalvular complica-
tion, New York Heart Association class 3 or 4 (versus 1 or 2),
aortic valve vegetation, new mitral or aortic valve regurgita-
tion, and causative microorganism (S aureus, coagulase-
negative staphylococci, and viridans group streptococci).
The predicted probabilities of surgery were calculated and
used as inverse probability weights in models predicting
outcome. Weights were trimmed at 20 to avoid overly
inﬂuential observations.
Model Derivation
The primary outcome variable was 6-month mortality. This
information was coded as time-to-event data using an
indicator of alive and time (in days) from admission to either
death or 6 months after discharge for those who were alive at
that time. Variables previously shown to be associated with
survival in IE were selected a priori and included age in years
(as categories ≤45, 46–60, 61–70, and >70), history of
hemodialysis, diabetes mellitus, injection drug use, time
of >1 month from ﬁrst IE manifestation to admission,
hospital-acquired infection, prosthetic valve IE, causative
microorganism, aortic or mitral valve regurgitation, aortic valve
vegetation, mitral valve vegetation, paravalvular complication,
heart failure, New York Heart Association class 3 or 4 heart
failure, stroke, embolization, persistent bacteremia, and surgery.
The variables included in the ﬁnal parsimonious derivation
model were selected as follows. A Cox proportional hazards
model predicting survival at 6 months after discharge was ﬁt
in the ICE-PCS data set, including all of the predictor variables
listed above. Surgery was included as a time-dependent
variable. The model was weighted by the inverse probability
(propensity) of surgery. This “full” model was ﬁt on 1000
bootstrap samples from the ICE-PCS data. Variables that were
Table 4. Proportional Hazards Model Results for the ICE-PCS Derivation (n=2646) and ICE-PLUS Validation (n=887) Cohorts and
6-Month Mortality
Variable
ICE-PCS ICE-PLUS
HR (95% CI) P Value HR (95% CI) P Value
Age 46–60 y 1.51 (1.29–1.78) <0.0001 1.69 (1.28–2.25) 0.0003
Age 61–70 y 1.87 (1.58–2.20) <0.0001 1.79 (1.34–2.40) <0.0001
Age >70 y 2.90 (2.50–3.37) <0.0001 3.09 (2.40–4.01) <0.0001
History of dialysis 2.04 (1.80–2.31) <0.0001 2.08 (1.56–2.73) <0.0001
Nosocomial IE 1.47 (1.33–1.63) <0.0001 1.48 (1.23–1.77) <0.0001
Prosthetic IE 1.20 (1.09–1.32) 0.0002 1.09 (0.92–1.30) 0.33
IE symptom onset to admission >30 days 0.74 (0.65–0.84) <0.0001 1.08 (0.90–1.29) 0.42
Staphylococcus aureus IE 1.42 (1.29–1.56) <0.0001 1.55 (1.30–1.86) <0.0001
Viridans group IE 0.63 (0.53–0.75) <0.0001 0.80 (0.62–1.02) 0.08
Aortic vegetation 1.21 (1.09–1.33) 0.0002 1.21 (1.03–1.42) 0.02
Mitral vegetation 1.20 (1.08–1.32) 0.0004 0.99 (0.92–1.02) 0.63
NYHA class 3 or 4 2.19 (2.00–2.39) <0.0001 1.60 (1.20–2.10) 0.0009
Stroke 1.76 (1.60–1.94) <0.0001 1.65 (1.39–1.94) <0.0001
Paravalvular complication 1.47 (1.34–1.61) <0.0001 1.32 (1.13–1.54) 0.0005
Persistent bacteremia 1.53 (1.35–1.72) <0.0001 1.92 (1.56–2.35) <0.0001
Surgical treatment 0.66 (0.60–0.74) <0.0001 0.74 (0.62–0.89) 0.0012
Harrell’s C statistic 0.715 0.682
HR indicates hazard ratio; ICE, International Collaboration on Endocarditis; IE, infective endocarditis; NYHA, New York Heart Association; PCS, Prospective Cohort Study.
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signiﬁcant at P<0.05 in ≥90% of the bootstrap samples were
included in the ﬁnal model. In addition, several variables were
included based on the previously described a priori criteria.
The proportional hazards assumption was evaluated
graphically through an analysis of Schoenfeld residuals. These
residuals were plotted against time for each variable in the
ﬁnal model and examined for systematic deviations from
constancy.
Model Validation
For internal validation, 1000 bootstrap samples were selected
from the ICE-PCS data set. Propensity score for surgery was
estimated for each sample and used for inverse weighting in
proportional hazards models predicting survival at 6 months
after discharge. These models included the same variables as
those in the ﬁnal development model. Harrell’s C statistic14
was calculated for each of these samples for comparison to
that estimated from the model in the ICE-PCS data set.
Because survival models include time to event as well as
event, this index of predictive discrimination includes both
outcome and time to outcome in determining concordance.
Each event (death) was paired with all other observations, and
the pairs were considered concordant (1) for event/nonevent
pairs, if the predicted probability of event was higher than the
paired nonevent or (2) for event/event pairs, if the predicted
probability of event was higher and the time to event was
smaller, or the converse. Harrell’s C statistic is the proportion
of all pairs that were concordant.
For external model validation, the variables from the ﬁnal
prediction model derived from the ICE-PCS data set were ﬁt in
a proportional hazards model in the ICE-PLUS data set. As
with the development model, this model was weighted by the
inverse probability of surgery from the ICE-PLUS propensity
model. Harrell’s C statistic was used to compare the
performance of the models in ICE-PCS and ICE-PLUS.14
In another evaluation of model performance, a risk score
was derived from the parameter estimates in the ﬁnal Cox
proportional hazards model. Each variable in the model was
assigned an integer value based on the relative size of the
parameter estimates. The risk score was then the sum of the
products of the integer value times the variable value, and
these were stratiﬁed into quintiles. The risk score ranged
between 0 and 22, and the risk score ranges in the quintiles
Figure 1. Kaplan–Meier survival probabilities for the International Collaboration on
Endocarditis–Prospective Cohort Study derivation cohort by quintiles of simpliﬁed risk
score.
DOI: 10.1161/JAHA.115.003016 Journal of the American Heart Association 5
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were 0 to 6, 7 to 8, 9 to 10, 11 to 16, and 17 to 22. Kaplan–
Meier cumulative survival probabilities were plotted by
stratum of risk score, and a log-rank test was used to
determine statistical difference among the curves. Receiver
operating characteristic analysis was performed for the
simpliﬁed risk score to determine sensitivity and speciﬁcity
for predicting 6-month mortality.
Sensitivity Analysis
To determine whether geographic region confounded the
estimation derived from the Cox model in ICE-PCS, geo-
graphic region was added to the ﬁnal model with the levels
Europe, North America, South America, and other. In a second
sensitivity analysis, we added the Society of Thoracic
Surgeons (STS) IE score15 to the ﬁnal Cox model in the ICE-
PLUS data set. Finally, to evaluate the sensitivity of the
predictive model to variable selection, the bootstrap analysis
of the development data set was repeated on the full set of
variables selected a priori. The distribution of the Harrell’s C
values from this set of analyses was compared with those
from models with the reduced set of predictors.
Statistical analyses were performed using SAS version 9.4
software (SAS Institute), and plots were generated with S-plus
8.1 (TIBCO Software Inc).
Results
The overall clinical characteristics of the 2 cohorts are shown
in Tables 1 and 2, including stratiﬁcation by survival to
6 months after hospital discharge. In ICE-PCS (n=4049), 777
(19.2%) patients died in the hospital and 971 (24.0%) had died
at 6-month follow-up; in ICE-PLUS (n=1197), 286 (23.9%) died
in the hospital and 342 (28.6%) had died at 6 months.
Characteristics strongly associated with 6-month mortality
included hospital-acquired infection, diabetes mellitus, renal
disease, hemodialysis, S aureus infection, heart failure and its
severity, persistent bacteremia, and stroke.
Surgery was performed in 1949 of 4049 (48.1%) of ICE-
PCS patients and 647 of 1197 (54.0%) of ICE-PLUS patients. A
high percentage of patients who underwent surgery were
transferred to the ICE sites (58% in ICE-PCS and 60% in ICE-
PLUS). Surgery was performed at a median of 7 days
(interquartile range 3–17 days) in ICE-PCS and 6 days
Figure 2. Kaplan–Meier survival probabilities for the International Collaboration on
Endocarditis–PLUS validation cohort by quintiles of simpliﬁed risk score.
DOI: 10.1161/JAHA.115.003016 Journal of the American Heart Association 6
IE Mortality Risk Score Park et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
(interquartile range 2–16 days) in ICE-PLUS. Types of valve
surgeries performed are shown in Table 3. In-hospital
mortality in patients who underwent surgery was 313 of
1949 (16.1%) in ICE-PCS and 125 of 647 (19.3%) in ICE-PLUS;
the 6-month mortality in surgically treated patients was 19.2%
in ICE-PCS and 22.6% in ICE-PLUS.
The proportional hazards model results are summarized in
Table 4. Patient age and complications of IE, particularly
advanced heart failure symptoms and stroke, were most
strongly associated with mortality; viridans streptococcal
infection and surgery were associated with lower mortality.
The ICE-PLUS model included the same variables that were in
the ICE-PCS model; no model reduction was performed.
Kaplan–Meier survival curves for the proportional hazards
models are shown in Figures 1 and 2. Variables associated
with complicated IE were present in higher percentages
across the quintiles of risk, including older age, comorbid
medical conditions, and IE complications; however, there was
an inverse relationship between use of surgery and predicted
6-month mortality. The direction and strength of the
associations were consistent across both IE cohorts. Harrell’s
C statistic was 0.715 for the derivation model and 0.682 for
the validation model.
A simpliﬁed, weighted risk score was developed (Table 5)
and correlated with observed 6-month mortality (adjusted
R2=0.91 and R2=0.97 for ICE-PCS and ICE-PLUS cohorts,
respectively) (Figure 3). Using the simpliﬁed risk score,
quintiles of risk for 6-month mortality were calculated, and
the clinical characteristics of these subgroups are shown in
Table 6. The 6-month mortality rates for these quintiles are
shown in Figure 4. Receiver operating characteristics for the
simpliﬁed risk score in the ICE-PCS derivation cohort are
shown in Figure 5. A simpliﬁed risk score ≥8 had sensitivity
86.7% and speciﬁcity 50.8% for predicting overall 6-month
mortality (negative predictive value of 86% and positive
predictive value of 39%).
Sensitivity analysis for geographic region was performed in
the derivation model for predicting 6-month mortality.
Although geographic regions of North and South Americas
were associated with a lower risk of mortality, the variables in
the model were unchanged when geographic region was
added. Similarly, sensitivity analysis of the validation model
found a signiﬁcant association for Society of Thoracic
Surgeons IE score, but other variables including surgery
remained statistically associated with mortality. In assessing
the effect of variable selection on model ﬁt, there was no
important difference in Harrell’s C statistic comparing the ﬁnal
derivation model with one including all of the variables
selected a priori. The Schoenfeld residuals analysis revealed
no violations of the proportional hazards assumption in the
ﬁnal derivation model.
Discussion
IE is often associated with serious complications, such as
heart failure from progressive tissue destruction, stroke, and
sepsis, yet other host and IE characteristics may also affect
longer term survival. We derived and validated a simpliﬁed risk
score for predicting 6-month mortality in IE using readily
available clinical variables at the time of IE diagnosis. The
prognostic signiﬁcance of these variables on outcome was
independent of surgical intervention, which was associated
with a lower risk of mortality at 6 months after adjustment for
surgical propensity. These independent and weighted risk
factors for mortality were developed from a large prospective
multinational data set and validated in a separate prospective
multinational cohort of IE.
Previous studies have evaluated clinical characteristics
associated with mortality in IE, generally focusing on in-hospital
mortality.13 In the ICE-PCS cohort, in-hospital mortality was
associated with IE complications of prosthetic or mitral valve IE,
Table 5. Simpliﬁed Risk Score Calculation for 6-Month
Mortality in IE
Prognostic Variable Weight
Constant 4
Host factors
Age ≤45 y 0
Age 46–60 y 2
Age 61–70 y 3
Age >70 y 4
History of dialysis 3
IE factors
Nosocomial IE 2
Prosthetic IE 1
Symptoms >1 month before admission 1
Staphylococcus aureus 1
Viridans group streptococci 2
Aortic vegetation 1
Mitral vegetation 1
IE complications
NYHA class 3 or 4 heart failure 3
Stroke 2
Paravalvular complication 2
Persistent bacteremia 2
Surgical treatment 2
Probability of 6-month mortality=2.4169score+0.1099score24.849. IE indicates
infective endocarditis; NYHA, New York Heart Association.
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pulmonary edema, paravalvular complication, and S aureus
infection.1 Longer term studies have demonstrated higher
mortality rates in IE patients beyond the index hospitalization,
predominantly due to noncardiovascular conditions.4,5 A recent
study from Taiwan using administrative claims also found
higher risk of cardiovascular events in long-term follow-up.5 In
our previous study of 1-year survival after prosthetic valve
endocarditis, the rate of mortality remained high for the ﬁrst
4 months after admission for IE in patients treated withmedical
therapy alone or in combination with surgery.16
Predictors of intermediate-term mortality have also been
evaluated in other studies of IE. In a retrospective regional
study of left-sided IE, abnormal mental status, comorbid
illness, moderate to severe heart failure, microbiologic
organism at baseline, and medical therapy were associated
with 6-month mortality in a logistic regression model.8 This
model was validated in a split-sample cohort but was limited
to patients with complicated left-sided IE and did not evaluate
surgery as a time-dependent covariate.8 In a more recent
retrospective study of possible or deﬁnite IE, Sy et al
evaluated the time-dependent nature of these clinical char-
acteristics during the index hospitalization. Whereas several
variables of acute physiology (eg, heart rate, serum creatinine,
platelet count) were associated with 6-month mortality on day
1, only heart failure, comorbid illness, and platelet count at
15 days were associated with this outcome.9 Furthermore,
surgery, which was performed in 57 of 192 patients, was not
signiﬁcantly associated with lower 6-month mortality.9
The present study conﬁrms many of these previous
ﬁndings and extends the risk association to include a number
of other baseline variables (including host factors of age and
dialysis) and other IE complications, such as stroke or
persistent bacteremia. A simpliﬁed weighted ICE prognostic
score was developed for clinical use, and these prognostic
factors for mortality were categorized into 4 groups of
variables: host factors, IE characteristics, complications, and
treatment with or without surgery. Many of the variables
predictive of 6-month mortality, ranging from 10% to >50%
across risk quintiles, have been associated previously with
mortality during the index hospitalization,1,13 and our risk
score emphasizes the additive prognostic associations of
these clinical characteristics.
We found signiﬁcant independent associations between
mortality and nearly all IE complications that are accepted
indications for surgical intervention.6,17 Importantly, in the
validated model using the ICE-PLUS cohort, all IE complica-
tions that predicted mortality occurred before surgery was
performed in those patients, illustrating the longer term
prognostic signiﬁcance of these sequelae, even with surgical
treatment. The additional strengths of our study that improve
the generalizability of the ﬁndings include the larger sample
sizes in both derivation and validation cohorts; separate
derivation and external validation cohorts of deﬁnite IE,
including different years of data collection; consistency of the
results despite differences in the 2 cohorts; and the
contemporary, prospective, multinational data collection.
Figure 3. Relationships between simpliﬁed infective endocarditis risk scores and
observed 6-month mortality in ICE-PCS derivation cohort and ICE-PCS validation cohorts.
Adjusted R2=0.91 and R2=0.97 for ICE-PCS and ICE-PLUS cohorts, respectively. ICE
indicates International Collaboration on Endocarditis; PCS, Prospective Cohort Study.
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Surgery was found to be independently associated with
lower 6-month mortality in our risk models, even after
adjustment for operative propensity and risk; however, surgery
was performed less frequently in the subgroups of patients with
highest risk of 6-month mortality, illustrating the selection bias
for this intervention even in the presence of indications. Our
recent study of surgical indications and treatment in the ICE-
PLUS cohort found that approximately one-quarter of left-sided
IE cases with indications for surgery did not undergo surgery
due to operative risk factors, such as sepsis, but that surgery
was associated with a survival beneﬁt after adjustment for
operative risk.12 The present study highlights the risk of death
related to host and IE characteristics even beyond the period of
surgical intervention. Multidisciplinary strategies for manage-
ment of IE cases by cardiologists, infectious disease specialists,
and cardiac surgeons have been found to improve survival,18,19
but additional studies are needed to optimize the use of surgery
in higher risk patients.
Our study has several limitations. All participating ICE
sites are referral centers with multidisciplinary experience in
the management of IE and the availability of cardiac surgery,
which may affect the generalizability of the results. Regional
differences in IE characteristics and treatment may exist
within the cohort, but sensitivity analysis by geographic
Table 6. Comparison of Clinical Characteristics of IE in the International Collaboration on Endocarditis–PLUS Cohort by Quintiles
of Risk for 6-Month Mortality
Variable
Quintile of Risk for 6-Month Mortality
P Value1 (n=224) 2 (n=188) 3 (n=200) 4 (n=98) 5 (n=172)
Host factors
Age ≤45 y 58.9 16.5 11.0 6.1 1.7 <0.001
Age 46–60 y 23.7 33.5 19.5 19.4 9.9
Age 61–70 y 12.1 23.4 18.5 30.6 26.2
Age >70 y 5.4 26.6 51.0 43.9 62.2
History of dialysis 0.4 2.1 1.5 7.1 16.3 <0.001
History of diabetes 7.1 14.9 23.0 27.6 36.0 <0.001
IE factors
Nosocomial IE 0.9 7.4 14.0 28.6 44.8 <0.001
Prosthetic IE 14.3 25 33.0 35.7 41.3 <0.001
Staphylococcus aureus 12.1 18.6 19.0 24.5 42.4 <0.001
Viridans group streptococci 36.2 19.1 12.0 6.1 1.2 <0.001
Aortic vegetation 33.0 44.1 43.0 37.8 46.5 0.048
Mitral vegetation 42.9 42 53.5 52.0 53.5 0.067
IE complications
NYHA class 3 or 4 0.0 2.7 4.5 10.2 14.5 <0.001
Stroke 9.4 14.4 20.0 28.6 41.3 <0.001
Paravalvular complication 17.0 27.7 42.0 42.9 50.6 <0.001
Persistent bacteremia 4.0 4.8 8.0 17.3 26.7 <0.001
Surgical treatment 79.9 67.6 47.0 35.7 25.0 <0.001
6-month mortality 10.3 17.0 25.5 37.8 52.9 <0.001
IE indicates infective endocarditis; NYHA, New York Heart Association.
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Figure 4. Mortality at 6 months by quintiles of simpliﬁed risk
score in the development and validation cohorts. ICE indicates
International Collaboration on Endocarditis; PCS, Prospective
Cohort Study.
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region did not substantially change the hazard ratios for
mortality in the derivation model. The use of surgery was not
prespeciﬁed by a study protocol, but we have previously
found that surgery was performed for guideline-directed
indications6,7 in the ICE-PLUS cohort.12 Although treatment
selection bias for surgery may inﬂuence the results of the
present study, surgical intervention was evaluated as a time-
dependent variable with inverse probability adjustment for
surgery in both models. Other clinical variables not collected
or included in the models may be associated with mortality
or may confound the relationships between deﬁned variables
and outcome.
In summary, clinical characteristics of the host, pathogen,
IE episode, and surgical treatment are independently associ-
ated with 6-month mortality in IE. A simpliﬁed prognostic
score may be used to identify speciﬁc risk subgroups to
compare treatment strategies and to optimize the use and
timing of surgery.
Appendix
ICE Participating Sites
Last updated: November 19, 2014
Argentina: Liliana Clara, MD, Marisa Sanchez, MD (Hospi-
tal Italiano). Jose Casabe, MD, PhD, Claudia Cortes, MD,
(Hospital Universitario de la Fundacion Favaloro). Francisco
Nacinovich, MD, Pablo Fernandez Oses, MD, Ricardo
Ronderos, MD, Adriana Sucari, MD, Jorge Thierer, MD
(Instituto Cardiovascular). Javier Altclas, MD, Silvia Kogan,
MD (Sanatorio de la Trinidad Mitre). Australia: Denis Spelman,
MD (Alfred Hospital). Eugene Athan, MD, Owen Harris, MBBS,
(Barwon Health). Karina Kennedy, MBBS, Ren Tan, MBBS
(Canberra Hospital). David Gordon, MBBS, PhD, Lito Papani-
colas, MBBS (Flinders Medical Centre). Tony Korman, MD,
Despina Kotsanas, BSc (Hons) (Southern Health). Robyn
Dever, MD, Phillip Jones, MD, Pam Konecny, MD, Richard
Lawrence, MD, David Rees, MD, Suzanne Ryan, MHSc (St.
George Hospital). Michael P. Feneley, MD, John Harkness, MD,
Phillip Jones, MD, Suzanne Ryan, MHSc (St. Vincent’s). Phillip
Jones, MD, Suzanne Ryan, MHSc (Sutherland). Phillip Jones,
MD, Jeffrey Post, MD, Porl Reinbott, Suzanne Ryan, MHSc (The
University of New South Wales). Austria: Rainer Gattringer,
MD, Franz Wiesbauer, MD (Vienna General Hospital). Brazil:
Adriana Ribas Andrade, Ana Claudia Passos de Brito, Armenio
Costa Guimar~aes, MD (Ana Neri Hospital). Max Grinberg, MD,
PhD, Alfredo Jose Mansur MD, PhD, Rinaldo Focaccia
Siciliano, MD, Tania Mara Varejao Strabelli, MD, Marcelo Luiz
Campos Vieira, MD (Heart Institute (Incor), University of Sao
Paulo Medical School). Regina Aparecida de Medeiros Tranch-
esi, MD, Marcelo Goulart Paiva, MD (Hospital 9 de Julho).
Claudio Querido Fortes, MD, PhD (Hospital Universitario
Figure 5. Receiver operating characteristic analysis for simpliﬁed risk score in the
International Collaboration on Endocarditis–Prospective Cohort Study derivation
cohort.
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Clementino Fraga Filho/UFRJ). Auristela de Oliveira Ramos,
MD (Instituto Dante Pazzanese de Cardiologia). Clara Weksler,
MD, Giovanna Ferraiuoli, MD, Wilma Golebiovski, MD, (Insti-
tuto Nacional de Cardiologia), Cristiane Lamas, MD, MRCP,
PhD (Unigranrio and Instituto Nacional de Cardiologia, Rio de
Janeiro). Canada: James A. Karlowsky, MD, Yoav Keynan, MD,
Andrew M. Morris, MD, Ethan Rubinstein, MD, LL.B (University
of Manitoba). Chile: Sandra Braun Jones, MD, Patricia Garcia,
MD (Hospital Clınico Pont. Universidad Catolica de Chile). M.
Cereceda, MD, Alberto Fica, Rodrigo Montagna Mella, Md
(Hospital Clinico Universidad de Chile). Columbia: Ricardo
Fernandez, MD, Liliana Franco, MD, Javier Gonzalez, MD,
Astrid Natalia Jaramillo, MD (Clinica Cardiovascular Medellın).
Croatia: Bruno Barsic, MD, PhD, Suzana Bukovski, MD, PhD
Vladimir Krajinovic, MD, Ana Pangercic, MD, Igor Rudez, MD,
Josip Vincelj, MD, PhD (University Hospital for Infectious
Diseases). Czech Republic: Tomas Freiberger, MD, PhD,
(Ceitec, Masaryk University, Brno) Jiri Pol, MD, Barbora
Zaloudikova, MSc (Centre for Cardiovascular Surgery and
Transplantation). Egypt: Zainab Ashour, MD, Amani El Kholy,
MD, Marwa Mishaal, MD, Dina Osama, MD, Hussien Rizk, MD
(Cairo University Medical School). France: Neijla Aissa, MD,
Corentine Alauzet, MD, Francois Alla, MD, PhD, CHU Cather-
ine Campagnac, RN, Thanh Doco-Lecompte, MD, Christine
Selton-Suty, MD (CHU Nancy-Brabois). Jean-Paul Casalta, MD,
Pierre-Edouard Fournier, MD, Gilbert Habib, MD, Didier Raoult,
MD, PhD, Franck Thuny, MD (Faculte de Medecine de
Marseille). Francois Delahaye, MD, PhD, Armelle Delahaye,
Francois Vandenesch, MD (Hospital Louis Pradel). Erwan
Donal, MD, Pierre Yves Donnio, PhD, Erwan Flecher, MD, PhD,
Christian Michelet, MD, PhD, Matthieu Revest, MD, Pierre
Tattevin, MD, PhD, (Pontchaillou University). Florent Chevalier,
MD, Antoine Jeu, MD, Jean Paul Remadi, MD, Dan Rusinaru,
MD, Christophe Tribouilloy, MD, PhD (South Hospital Amiens).
Yvette Bernard, MD, Catherine Chirouze, MD, Bruno Hoen,
MD, PhD, Joel Leroy, MD, Patrick Plesiat, MD (University
Medical Center of Besancon). Germany: Christoph Naber,
MD, PhD, Carl Neuerburg (Universitaetskliniken Bergmannsheil
Bochum). Bahram Mazaheri, PhD, Christoph Naber, MD, PhD,
Carl Neuerburg (University Essen). Greece: Sophia Athanasia,
Ioannis Deliolanis, Helen Giamarellou, MD, PhD, Tsaganos
Thomas, MD, Efthymia Giannitsioti, MD (Attikon University
General Hospital). Elena Mylona, MD, Olga Paniara, MD, PhD,
Konstantinos Papanicolaou, MD, John Pyros, MD, Athanasios
Skoutelis, MD, PhD (Evangelismos General Hospital of Athens).
Elena Mylona, MD, Olga Paniara, MD, PhD, Konstantinos
Papanikolaou, MD, John Pyros, MD, Athanasios Skoutelis, MD,
PhD (Evangelismos General Hospital of Athens). India: Gautam
Sharma, MD (All India Institute of Medical Sciences). Johnson
Francis, MD, DM, Lathi Nair, MD, DM Vinod Thomas, MD, DM,
Krishnan Venugopal, MD, DM (Medical College Calicut).
Ireland: Margaret M. Hannan, MB, BCh BAO, MSc, John P.
Hurley, MB, BCh (Mater Hospitals). Israel: Amos Cahan, MD,
Dan Gilon, MD, Sarah Israel, MD, Maya Korem, MD, Jacob
Strahilevitz, MD (Hadassah-Hebrew University).Ethan Rubin-
stein, MD, LL.B, Jacob Strahilevitz, MD (Tel Aviv University
School of Medicine). Italy: Emanuele Durante-Mangoni, MD,
PhD, Irene Mattucci, MD, Daniela Pinto, MD, Federica Agrusta,
MD, Alessandra Senese, MD, Enrico Ragone, MD, PhD,
Riccardo Utili, MD, PhD (II Universita di Napoli). Enrico Cecchi,
MD, Francesco De Rosa, MD, Davide Forno, MD, Massimo
Imazio, MD, Rita Trinchero, MD (Maria Vittoria Hospital). Paolo
Grossi, MD, PhD, Mariangela Lattanzio, MD, Antonio Toniolo,
MD (Ospedale di Circolo Varese). Antonio Goglio, MD,
Annibale Raglio, MD, DTM&H, Veronica Ravasio, MD, Marco
Rizzi, MD, Fredy Suter, MD (Ospedali Riuniti di Bergamo).
Giampiero Carosi, MD, Silvia Magri, MD, Liana Signorini, MD
(Spedali Civili – Universita di Brescia). Lebanon: Zeina
Kanafani, MD, MS, Souha S.Kanj, MD, Ahmad Sharif-Yakan,
MD (American University of Beirut Medical Center). Malaysia:
Imran Abidin, MD (University of Malaya Medical Center).
Syahidah Syed Tamin, MD (National Heart Institute). Mexico:
Eduardo Rivera Martınez, MD, Gabriel Israel Soto Nieto, MD
(Instituto Nacional de Cardiologıa Ignacio Chavez). Nether-
lands: Jan T.M. van der Meer, MD, PhD (University of
Amsterdam). New Zealand: Stephen Chambers, MD, MSc
(University of Otago), David Holland, MB, ChB, PhD (Middle-
more Hospital), Arthur Morris, MD (Diagnostic Medlab), Nigel
Raymond, MB, ChB (Wellington Hospital), Kerry Read, MB,
ChB (North Shore Hospital). David R. Murdoch, MD, MSc,
DTM&H (University of Otago). Romania: Stefan Dragulescu,
MD, PhD, Adina Ionac, MD, PhD, Cristian Mornos, MD (Victor
Babes University of Medicine and Pharmacy). Russia: O.M.
Butkevich, PhD (Learning-Scientiﬁc Centre of Medical Centre
of Russian Presidential Affairs Government Medical Centre of
Russian). Natalia Chipigina, PhD, Ozerecky Kirill, MD,
Kulichenko Vadim, Tatiana Vinogradova, MD, PhD (Russian
Medical State University). Saudi Arabia: Jameela Edathodu,
MBBS, Magid Halim, MBBS (King Faisal Specialist Hospital &
Research Center). Singapore: Yee-Yun Liew, Ru-San Tan,
MBBS (National Heart Centre). Slovenia: Tatjana Lejko-
Zupanc, MD, PhD, Mateja Logar, MD, PhD, Manica Mueller-
Premru, MD, PhD (Medical Center Ljublijana). South Africa:
Patrick Commerford, MD, Anita Commerford, MD, Eduan
Deetlefs, MD, Cass Hansa, MD, Mpiko Ntsekhe, MD (Univer-
sity of Cape Town and Groote Schuur Hospital). Spain:
Manuel Almela, MD, Yolanda Armero, MD, Manuel Azqueta,
MD, Ximena Casta~neda, MD, Carlos Cervera, MD, PhD, MD,
PhD, Carlos Falces, MD, PhD, Cristina Garcia-de-la-Maria,
PhD, Guillermina Fita, MD, Jose M. Gatell, MD, PhD, Magda
Heras, MD, PhD Jaime Llopis, MD, PhD, Francesc Marco, MD,
PhD, Carlos A. Mestres, MD, PhD, Jose M. Miro, MD, PhD,
Asuncion Moreno, MD, PhD, Salvador Ninot, MD, Carlos Pare,
MD, PhD Juan M. Pericas, MD, Jose Ramirez, MD, PhD, Irene
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Rovira, MD, Marta Sitges, MD, PhD (Hospital Clinic – IDIBAPS.
University of Barcelona, Barcelona, Spain). University of
Barcelona, Barcelona, Spain). Ignasi Anguera, MD, PhD, Bernat
Font, MD, Joan Raimon Guma, MD (Hospital de Sabadell).
Javier Bermejo, Emilio Bouza, MD, PhD, Miguel Angel Garcia
Fernandez, MD, Victor Gonzalez-Ramallo, MD, Mercedes
Marın, MD, Patricia Mu~noz, MD, PhD, Miguel Pedromingo,
MD, Jorge Roda, Marta Rodrıguez-Creixems, MD, PhD, Jorge
Solis, MD (Hospital General Universitario Gregorio Mara~non).
Benito Almirante, MD, Nuria Fernandez-Hidalgo, MD, Pilar
Tornos, MD (Hospital Universitari Vall d’Hebron). Arıstides de
Alarcon, Ricardo Parra (Hospital Universitario Virgen del Rocıo).
Sweden: Eric Alestig, MD, Magnus Johansson, MD, PhD, Lars
Olaison, MD, PhD, Ulrika Snygg-Martin, MD (Sahlgrenska
Universitetssjukhuset/€Ostra). Thailand: Orathai Pachirat, MD,
Pimchitra Pachirat, MD, Burabha Pussadhamma, MD, Vichai
Senthong, MD (Khon Kaen University). United Kingdom: Anna
Casey, MBBS, Tom Elliott, PhD, DSc, Peter Lambert, BSc, PhD,
DSc, Richard Watkin, MBBS (Queen Elizabeth Hospital).
Christina Eyton, John L. Klein, MD (St. Thomas’ Hospital).
United States of America: Suzanne Bradley, MD, Carol
Kauffman, MD (Ann Arbor VA Medical Center). Roger Bedimo,
MD, MS (Dallas VA Medical Center). Vivian H. Chu, MD, MHS,
G. Ralph Corey, MD, Anna Lisa Crowley, MD, MHS, Pamela
Douglas, MD, Laura Drew, RN, BSN, Vance G. Fowler, MD,
MHS, Thomas Holland, MD, Tahaniyat Lalani, MBBS, MHS,
Daniel Mudrick, MD, Zaniab Samad, MD, MHS, Daniel Sexton,
MD, Martin Stryjewski, MD, MHS, Andrew Wang, MD,
Christopher W. Woods, MD, MPH (Duke University Medical
Center). Stamatios Lerakis, MD (Emory University). Robert
Cantey, MD, Lisa Steed, PhD, Dannah Wray, MD, MHS
(Medical University of South Carolina). Stuart A. Dickerman,
MD (New York University Medical Center). Hector Bonilla, MD,
Joseph DiPersio, MD, PhD, Sara-Jane Salstrom, RN (Summa
Health System). John Baddley, MD, Mukesh Patel, MD
(University of Alabama at Birmingham). Gail Peterson, MD,
Amy Stancoven, MD (UT-Southwestern Medical Center).
Donald Levine, MD, Jonathan Riddle, Michael Rybak, PharmD,
MPH (Wayne State University). Christopher H. Cabell, MD,
MHS (Quintiles).
ICE Coordinating Center: Khaula Baloch, MPH, Vivian H.
Chu, MD, MHS, G. Ralph Corey, MD, Christy C. Dixon, Vance
G. Fowler Jr, MD, MHS, Tina Harding, RN, BSN, Marian Jones-
Richmond, Lawrence P. Park, PhD, Bob Sanderford, Judy
Stafford, MS.
ICE Publications Committee: Kevin Anstrom, PhD,
Eugene Athan, MD, Arnold S. Bayer, MD, Christopher H.
Cabell, MD, MHS, Vivian H. Chu, MD, MHS, G. Ralph Corey,
MD, Vance G. Fowler, Jr, MD, MHS, Bruno Hoen, MD, PhD,
A. W. Karchmer, MD, Jose M. Miro, MD, PhD, David R.
Murdoch, MD, MSc, DTM&H, Daniel J. Sexton, MD, Andrew
Wang, MD.
ICE Steering Committee: Arnold S. Bayer, MD, Christo-
pher H. Cabell, MD, MHS, Vivian Chu, MD, MHS. G. Ralph
Corey, D, David T. Durack, MD, D Phil, Susannah Eykyn, MD,
Vance G. Fowler, Jr, MD, MHS, Bruno Hoen, MD, PhD, Jose M.
Miro, MD, PhD, Phillipe Moreillon, MD, PhD, Lars Olaison, MD,
PhD, Didier Raoult, MD, PhD, Ethan Rubinstein, MD, LLB,
Daniel J. Sexton, MD.
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